Noninvasive Prenatal Technique Detects Subchromosomal Abnormalities
By LabMedica International staff writers Posted on 24 Nov 2015 |
Image: Detection of chromosomal deletion by NIPT using maternal blood plasma (top) is similar to detection with the traditional method using fetal tissue (bottom) (Photo courtesy of UC San Diego Health).
Image: The Ion Proton Sequencer System (Photo courtesy of Life Technologies).
Noninvasive prenatal testing (NIPT) using sequencing of fetal cell-free DNA from maternal plasma has allowed accurate prenatal diagnosis of aneuploidy without requirement of an invasive procedure and this approach has gained increasing clinical acceptance.
A novel technique has been developed that uses a semiconductor sequencing platform to identify small chromosomal deletions or duplications, such as occur in Cri du Chat Syndrome and DiGeorge Syndrome, with a simple blood test from the expectant mother.
An international team of scientists including those at the University of California, San Diego School of Medicine (La Jolla, CA, USA) analyzed blood plasma from 1,476 pregnant women with fetal structural abnormalities detected by ultrasound. These women also underwent an invasive diagnostic procedure and conventional fetal DNA analysis. The scientists compared that information to semiconductor sequencing results on circulating fetal DNA obtained from a blood test on the pregnant women at an average gestational age of 24 weeks.
After DNA extraction, a comparative genomic hybridization analysis (aCGH) was performed using Agilent commercial arrays (Agilent Technologies; Santa Clara, CA, USA). To obtain complete sequences of cell-free DNA (cfDNA) fragments, sequencing was performed using an Ion Proton Sequencer (Life Technologies; Carlsbad, CA, USA). The new semiconductor sequencing method detected 69 of 73 (94.5%) abnormalities of a certain size (greater than one million base pairs) detected by the conventional method. According to the investigators, the cost of NIPT with semiconductor sequencing has the potential to be less expensive than the conventional, invasive prenatal testing method, especially as genetic sequencing technologies continue to decrease in cost.
In the study, semiconductor sequencing detected 55 false positives, of which 35 (63.6%) were due to maternal, rather than fetal, chromosomal abnormalities. That means the new method will require a validation test to screen out maternal abnormalities. NIPT with semiconductor sequencing also needs to be tested at early time points in the pregnancy, at 12 to 16 weeks, and it is hoped to further improve the technique to be able to detect even smaller genetic abnormalities.
The authors concluded that methods they developed can be applied to any mixed biological sample to determine the subchromosomal abnormalities in the minor component, even when this fraction represents only a small percentage of the total DNA. In prenatal diagnostics, samples obtained from chorionic villi could be analyzed for mosaic karyotypes or maternal contamination. The study was published on November 11, 2015 in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
University of California, San Diego School of Medicine
Agilent Technologies
Life Technologies
A novel technique has been developed that uses a semiconductor sequencing platform to identify small chromosomal deletions or duplications, such as occur in Cri du Chat Syndrome and DiGeorge Syndrome, with a simple blood test from the expectant mother.
An international team of scientists including those at the University of California, San Diego School of Medicine (La Jolla, CA, USA) analyzed blood plasma from 1,476 pregnant women with fetal structural abnormalities detected by ultrasound. These women also underwent an invasive diagnostic procedure and conventional fetal DNA analysis. The scientists compared that information to semiconductor sequencing results on circulating fetal DNA obtained from a blood test on the pregnant women at an average gestational age of 24 weeks.
After DNA extraction, a comparative genomic hybridization analysis (aCGH) was performed using Agilent commercial arrays (Agilent Technologies; Santa Clara, CA, USA). To obtain complete sequences of cell-free DNA (cfDNA) fragments, sequencing was performed using an Ion Proton Sequencer (Life Technologies; Carlsbad, CA, USA). The new semiconductor sequencing method detected 69 of 73 (94.5%) abnormalities of a certain size (greater than one million base pairs) detected by the conventional method. According to the investigators, the cost of NIPT with semiconductor sequencing has the potential to be less expensive than the conventional, invasive prenatal testing method, especially as genetic sequencing technologies continue to decrease in cost.
In the study, semiconductor sequencing detected 55 false positives, of which 35 (63.6%) were due to maternal, rather than fetal, chromosomal abnormalities. That means the new method will require a validation test to screen out maternal abnormalities. NIPT with semiconductor sequencing also needs to be tested at early time points in the pregnancy, at 12 to 16 weeks, and it is hoped to further improve the technique to be able to detect even smaller genetic abnormalities.
The authors concluded that methods they developed can be applied to any mixed biological sample to determine the subchromosomal abnormalities in the minor component, even when this fraction represents only a small percentage of the total DNA. In prenatal diagnostics, samples obtained from chorionic villi could be analyzed for mosaic karyotypes or maternal contamination. The study was published on November 11, 2015 in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
University of California, San Diego School of Medicine
Agilent Technologies
Life Technologies
Latest Molecular Diagnostics News
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer